Corbus Pharmaceuticals (CRBP) announced that data from its US and UK conducted first-in-human dose escalation clinical study of CRB-701 is ...

The abstract, Phase 1 Dose-Escalation Study of Next-Generation Nectin-4 Targeting Antibody-Drug Conjugate CRB-701 (SYS6002) in US And UK Patients with Urothelial Cancer and other Solid Tumors ( Perez, ...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) announced that data from its US and UK first-in-human dose escalation ...

Corbus Pharmaceuticals presented new data from the first Western study of its antibody-drug conjugate treatment for cancer.

Corbus Pharmaceuticals (CRBP) stock drops 12% after mixed Phase 1 trial results for its lead cancer candidate. Read more here.

Happy V-Day! Gorge on heart-shaped chocolate and ponder the implications of RFK Jr. being sworn in as health secretary. Today, we talk about that, as well as new cancer data from Corbus Pharma, Europe ...

Analysts at HC Wainwright issued their FY2029 earnings estimates for shares of Corbus Pharmaceuticals in a note issued to investors on Monday, February 10th. HC Wainwright analyst A. Maldonado expects ...

NORWOOD, Mass. - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a $119 million market cap biopharmaceutical company, announced the release of an abstract detailing its Phase 1 clinical study of ...

HC Wainwright reaffirmed their buy rating on shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) in a research ...

H.C. Wainwright analyst Andres Y. Maldonado confirmed a Buy rating and a $75.00 price target on Corbus Pharmaceuticals (NASDAQ:CRBP), representing significant upside potential from the current price ...